Recent Stock Decline: Hims & Hers Health Inc. has seen its stock price drop recently, with a notable decline of over 3% in a single day following a price target cut by a major financial institution. Discussions on social media highlight concerns over the company’s ability to meet ambitious revenue goals for 2026. This has sparked debates about whether the current price reflects long-term challenges or a temporary setback.
Expansion Efforts: On a positive note, the company’s aggressive expansion into markets like Canada and the UK, along with new offerings in menopause care and lab testing, is generating buzz on social media. Many are intrigued by the potential for growth through these innovative health solutions. However, some express skepticism about profitability amid high marketing costs.
Note: This discussion summary was generated from an AI condensation of post data.
Hims & Hers Health Inc. Insider Trading Activity
Hims & Hers Health Inc. insiders have traded $HIMS stock on the open market 63 times in the past 6 months. Of those trades, 0 have been purchases and 63 have been sales.
Here’s a breakdown of recent trading of $HIMS stock by insiders over the last 6 months:
- ANDREW DUDUM (Chief Executive Officer) has made 0 purchases and 24 sales selling 1,252,093 shares for an estimated $62,715,056.
- OLUYEMI OKUPE (Chief Financial Officer) has made 0 purchases and 12 sales selling 366,861 shares for an estimated $19,435,678.
- MICHAEL CHI (Chief Operating Officer) has made 0 purchases and 10 sales selling 77,349 shares for an estimated $4,288,956.
- PATRICK HARRISON CARROLL (Chief Medical Officer) has made 0 purchases and 3 sales selling 80,042 shares for an estimated $4,088,809.
- SOLEIL BOUGHTON (Chief Legal Officer) has made 0 purchases and 10 sales selling 26,103 shares for an estimated $1,289,801.
- IRENE BECKLUND (PAO) has made 0 purchases and 2 sales selling 16,821 shares for an estimated $733,472.
- DEBORAH M. AUTOR (Chief Policy Officer) sold 7,054 shares for an estimated $258,952
- GARCIA ANDREA G PEREZ sold 2,500 shares for an estimated $97,925
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Hims & Hers Health Inc. Revenue
Hims & Hers Health Inc. had revenues of $599M in Q3 2025. This is an increase of 49.16% from the same period in the prior year.
You can track HIMS financials on Quiver Quantitative's HIMS stock page.
Hims & Hers Health Inc. Congressional Stock Trading
Members of Congress have traded $HIMS stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $HIMS stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN purchased up to $15,000 on 08/04.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Hims & Hers Health Inc. Hedge Fund Activity
We have seen 295 institutional investors add shares of Hims & Hers Health Inc. stock to their portfolio, and 240 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 15,045,710 shares (+549.0%) to their portfolio in Q3 2025, for an estimated $853,392,671
- SRS INVESTMENT MANAGEMENT, LLC removed 4,000,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $226,880,000
- TIDAL INVESTMENTS LLC added 2,707,111 shares (+1779.6%) to their portfolio in Q3 2025, for an estimated $153,547,335
- FARALLON CAPITAL MANAGEMENT LLC added 2,533,271 shares (+30.8%) to their portfolio in Q3 2025, for an estimated $143,687,131
- PRICE T ROWE ASSOCIATES INC /MD/ added 2,504,252 shares (+444.1%) to their portfolio in Q3 2025, for an estimated $142,041,173
- RENAISSANCE TECHNOLOGIES LLC added 2,227,400 shares (+32.4%) to their portfolio in Q3 2025, for an estimated $126,338,128
- D. E. SHAW & CO., INC. removed 1,886,971 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $107,028,995
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Hims & Hers Health Inc. Analyst Ratings
Wall Street analysts have issued reports on $HIMS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 11/04/2025
- B of A Securities issued a "Underperform" rating on 11/04/2025
- Canaccord Genuity issued a "Buy" rating on 09/12/2025
To track analyst ratings and price targets for Hims & Hers Health Inc., check out Quiver Quantitative's $HIMS forecast page.
Hims & Hers Health Inc. Price Targets
Multiple analysts have issued price targets for $HIMS recently. We have seen 5 analysts offer price targets for $HIMS in the last 6 months, with a median target of $48.0.
Here are some recent targets:
- Glen Santangelo from Barclays set a target price of $48.0 on 12/09/2025
- David Larsen from BTIG set a target price of $85.0 on 11/04/2025
- Allen Lutz from B of A Securities set a target price of $32.0 on 11/04/2025
- Maria Ripps from Canaccord Genuity set a target price of $68.0 on 09/12/2025
- Jailendra Singh from Truist Securities set a target price of $37.0 on 08/18/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
